Date: 2016-03-21
Type of information: Nomination
Compound:
Company: Ultragenyx Pharmaceutical (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 21, 2016, Ultragenyx Pharmaceutical announced the appointment of Lars Ekman, M.D., Ph.D., to the company's Board of Directors effective March 17, 2016. Dr. Ekman, Executive Partner at Sofinnova Ventures, will serve as an independent director to Ultragenyx. Dr. Ekman has more than 30 years of experience in senior executive, scientific, and clinical functions. Since 2008, he has served as executive partner at Sofinnova Ventures, a leading venture capital firm in biotechnology. Dr. Ekman previously served as president of research and development at Elan. He is credited with advancing the company's pipeline during this period, and under his leadership, Elan received approval for four U.S. New Drug Applications, three European Marketing Authorization Applications and five Investigational New Drug Applications. Prior to joining Elan, Dr. Ekman led research and development at Schwarz Pharma AG, and prior to that, held a variety of senior scientific and clinical roles at Pharmacia (now Pfizer).
Dr. Ekman serves as Chairman of Amarin Corporation plc, Sophiris Bio, Inc., and Prothena Corporation plc, and is a director of Spark Therapeutics, Inc.
Dr. Ekman is a board-certified surgeon with a Ph.D. in Experimental Biology and has held several clinical and academic positions in both the United States and Europe. He obtained his Ph.D. and M.D. from the University of Gothenburg, Sweden.
Financial terms:
Latest news:
